Overview
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Eligibility
Inclusion Criteria:
- Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.
- Have moderate to severe disease not adequately controlled by topical treatments.
- Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.
Exclusion Criteria:
- Have certain infections or other immune conditions.
- Recently used medications that could interfere with the study.
- Are pregnant or breastfeeding.